Herbix compound In The Facial Herpes.

Investigation Of The Effect Of Herbix compound In The Treatment Of Facial Herpes.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231030059908N2

Enrollment

Registered

2023-12-25

Start date

2024-01-21

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes simplex.

Interventions

Intervention 1: Intervention group: In addition to the standard treatment for Herpes Simplex, this group receives a new drug called Herbix. Intervention 2: Control group:They receive only the standard

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Clinical symptoms of herpes such as tingling and itching around the wound. Small blisters filled with liquid on the skin of the face. Scaling of small merged blisters. Fluid secretion.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
RNA extraction. Timepoint: At the beginning of the study, on the thirtieth day. Method of measurement: HDF fibroblast cell, 8-OH-dG, HSV-1 gene, caspase-3 gene, caspase-9 gene, Anti-Herpe.;Real-time Polymerase chain reaction investigation. Timepoint: At the beginning of the study, on the thirtieth day. Method of measurement: Commercial kit of Ben Yakhte company.;Antiviral antibody level in serum. Timepoint: At the beginning of the study, on the thirtieth day. Method of measurement: ELISA technique and abCAM company kit.;DNA damage. Timepoint: The beginning of the study. Method of measurement: 8-OH-dG level in culture supernatant.	—

Measure

Time frame

RNA extraction. Timepoint: At the beginning of the study, on the thirtieth day. Method of measurement: HDF fibroblast cell, 8-OH-dG, HSV-1 gene, caspase-3 gene, caspase-9 gene, Anti-Herpe.;Real-time Polymerase chain reaction investigation. Timepoint: At the beginning of the study, on the thirtieth day. Method of measurement: Commercial kit of Ben Yakhte company.;Antiviral antibody level in serum. Timepoint: At the beginning of the study, on the thirtieth day. Method of measurement: ELISA technique and abCAM company kit.;DNA damage. Timepoint: The beginning of the study. Method of measurement: 8-OH-dG level in culture supernatant.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza Keramatiyan

Islamic Azad University

keramatiyanGH1@gmail.com0098513529717

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026